MCED test kit CanScan™

oncologyblood

Cancer is a major global health challenge and a leading cause of death worldwide. According to the latest data from the World Health Organization (WHO), there are approximately 20 million new cancer cases and 9.7 million cancer deaths each year. The cancer burden is projected to increase by around 77% by 2050¹. Early detection and prevention are crucial, as the five-year survival rate for early-stage cancer is 89%, compared to only 20% for advanced-stage cancer. Notably, 59% of cancer deaths result from cancers that are not commonly screened for. Therefore, it is essential to detect cancer at an early stage using non-invasive, highly sensitive tests. MULTI-CANCER EARLY DETECTION (MCED) Detect cancer signals across different types of tumors Minimally invasive blood test capable of detecting early stage cancer signals before symptoms arise and predicting the tumor’s tissue of origin (TOO). Employs low-depth whole genome sequencing (WGS) to pinpoint various multidimensional features, including genomic, fragmentomic, and inferred epigenomic features carried by circulating free DNA (cfDNA). Highly sensitive tumor early detection technology, Mercury™. Tracing Accuracy 92% WHO IS IT FOR Recommended for individuals aged 45 and older with an average risk of cancer.